SCHEMBL3884047

SCHEMBL3884047

COc1ccc(NC(=O)C(=O)c2c(-c3ccccc3)cc3ccc(C#N)cn23)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.43
GAA P10253 1/20 0.43
MET P08581 1/20 0.42
KDR P35968 1/20 0.42
THRB P10828 1/20 0.42
LMNA P02545 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
HTT P42858 3/20 0.42
MAPK14 Q16539 1/20 0.42
MAPT P10636 4/20 0.41
ALDH1A1 P00352 3/20 0.41
RXFP1 Q9HBX9 1/20 0.41
KCNA5 P22460 1/20 0.40
PLAU P00749 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HDAC3 O15379 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
AURKA O14965 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1643301 0.89 POLB (0.49) POLBGAATHRBLMNASMN1; SMN2
SCHEMBL3885596 0.84 CYP19A1 (0.47) POLBGAATHRBLMNASMN1; SMN2
SCHEMBL1645639 0.84 SMN1; SMN2 (0.47) POLBGAATHRBLMNASMN1; SMN2
SCHEMBL1645631 0.83 SMN1; SMN2 (0.48) GAATHRBLMNASMN1; SMN2HTT
SCHEMBL1644769 0.83 THRB (0.61) POLBGAATHRBLMNASMN1; SMN2
SCHEMBL3886901 0.82 CYP19A1 (0.45) POLBGAATHRBLMNASMN1; SMN2
SCHEMBL1645179 0.82 MAPT (0.46) POLBGAATHRBLMNASMN1; SMN2
SCHEMBL1647218 0.81 L3MBTL1 (0.58) THRBLMNASMN1; SMN2HTTMAPT
SCHEMBL3890527 0.80 THRB (0.49) POLBGAATHRBLMNASMN1; SMN2
SCHEMBL1646571 0.78 LMNA (0.45) POLBTHRBLMNASMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8486962-B2 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus F2G LTD. (GB) 2013-07-16 US disclosed
EP-1888063-B1 ANTIFUNGAL AGENTS F2G LTD (GB) 2009-01-14 EP disclosed
US-20080161302-A1 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus F2G LTD. (GB) 2008-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161302-A1 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus NAT1, CYP1A2, CYP51A1 POLB 4574/4885GAA 705/4885MET 3950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.